A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed Multiple Myeloma(MM)
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Dexamethasone; Doxorubicin; Epidoxoform
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 11 Nov 2017 Status changed from active, no longer recruiting to completed.
- 06 Jul 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.